Form 4: Voyager Therapeutics Director Steven Hyman Granted 24,000 Stock Options

Steven Hyman, a Director at Voyager Therapeutics, Inc. (VYGR), was granted 24,000 stock options with an exercise price of $3.28 per share as part of the company's 2025 Stock Incentive Plan.

Summary

• Steven Hyman, a Director of Voyager Therapeutics, Inc. (VYGR), reported the acquisition of 24,000 derivative securities in the form of stock options.
• The transaction date for this grant was June 3, 2025.
• Each stock option has an exercise price of $3.28 per share.
• The options were issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc., in accordance with its director compensation policy.
• The vesting commencement date is the grant date (June 3, 2025).
• All shares underlying the option vest upon the earlier of the one-year anniversary of the vesting commencement date or the date of the next annual meeting of stockholders, subject to Mr. Hyman's continued service as a director.
• The expiration date for these stock options is June 3, 2035.
• Following this transaction, Steven Hyman beneficially owns 24,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The document reports a routine compensation event (stock option grant) to a director, which is a positive for the director and a neutral, expected event for the company, reflecting standard corporate governance and incentive practices. It does not indicate any significant positive or negative operational or financial news beyond this.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term performance.
• The transaction is part of a pre-established director compensation policy, indicating structured corporate governance regarding executive incentives.

Future Outlook

The stock options are subject to vesting based on Steven Hyman's continued service as a director, either until the one-year anniversary of the grant date or the next annual meeting of stockholders, whichever is earlier. This indicates an expectation of continued tenure and contribution from the director.

Management Comments

• "This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy."
• "All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director."

Industry Context

The granting of stock options to directors is a common practice across industries, including biotechnology, to attract and retain talent, and to align the interests of directors with those of shareholders. This filing reflects a standard compensation event within the sector.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a widely accepted practice in the biotechnology and pharmaceutical industries, similar to companies like Biogen Inc. or Sarepta Therapeutics, Inc., which also utilize equity-based incentives for their board members.
• The vesting schedule, tied to continued service, is a typical mechanism to ensure director commitment and long-term alignment, consistent with corporate governance benchmarks for public companies.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align the director's interests with those of the shareholders, potentially leading to better long-term decision-making and value creation.

Next Steps

• Steven Hyman's continued service as a director is required for the stock options to vest.

Key Dates

Keywords

Voyager Therapeutics, VYGR, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Steven Hyman, Biotechnology, Pharmaceuticals